Improdia is an innovative, diagnostic company that is developing a simple blood test, that monitors the chronic inflammation level of patients suffering from autoimmune and cancer diseases, reflecting the Immune status of patients.
Improdia’s novel technology has enormous potential both as a Prognostic/Diagnostic kit for a wide range of chronic inflammatory diseases.
Current tests cannot provide real-time diagnosis and monitoring and cannot distinguish between acute and chronic inflammation, or monitor the immune function.
The company’s core technology is based on its revolutionary biomarkers that covers both cells (MDSCs) and protein (CD247 & SNX9) levels.
